Supreme Court of the United States · Official docket →
Tessa Needham, et al. v. Merck & Company, Inc., et al.
Paid petition · United States Court of Appeals for the Fourth Circuit, No. 24-1828, 24-1831, 24-1832 · judgment September 4, 2025
Before the decision, well below the 4.1% base rate, with no standout signals pointing toward a grant.
Question presented
Did the Fourth Circuit Court of Appeals err by finding that a special masters’ findings in Plaintiffs’ claims filed in the Department of Health and Human Services administrative Vaccine Injury Compensation Plan (“VICP”) were entitled to res judicata effect when the Vaccine Act expressly allows a plaintiff to reject a VICP decision and file a de novo action in a district court? The Fourth Circuit’s decision below is contrary to Shalala v. Whitecotton, 514 U.S. 268 (1995). Did the Fourth Circuit Court of Appeals err by holding the National Childhood Injury Act (“Vaccine Act”), 42 U.S.C. §§ 300aa-1 et seq. was constitutional where Congress enacted a Vaccine Table in the Act itself listing the vaccines and injuries covered by the Act, but the Act purported to allow the Secretary of Health and Human Services by regulatory action alone to amend or repeal the vaccines and injuries covered by the Act without an act of Congress signed by the President, as required by the presentment clause of the United States Constitution, article I, section 7, clause 2? The Fourth Circuit’s decision below conflicts with Clinton v. City of New York, 524 U.S. 417, 438 (1998) (“There is no provision in the Constitution that authorizes the President to enact, to amend, or to repeal statutes.”) and Terran v. Secretary of Health and Human Services, 195 F.3d 1302, 1317-1321 (Fed. Cir. 1999) (Plager, J. Dissenting).
Counsel of record
For petitioner
Kenneth S. Robbins
Bronster Fujichaku Robbins
For respondent
Edward James Dumoulin
Goldman Ismail Tomaselli Brennan & Baum LLP
Proceedings
- Mar 30 2026Petition DENIED.
- Mar 11 2026DISTRIBUTED for Conference of 3/27/2026.
- Mar 05 2026Waiver of right of respondent Merck & Co., Inc., et al. to respond filed.
- Feb 02 2026Petition for a writ of certiorari filed. (Response due March 9, 2026)
- Dec 01 2025Application (25A615) granted by The Chief Justice extending the time to file until February 1, 2026.
- Nov 18 2025Application (25A615) to extend the time to file a petition for a writ of certiorari from December 3, 2025 to February 1, 2026, submitted to The Chief Justice.